Skip to content
ChickenStockChickenStock
ResearchRPRX
Royalty Pharma logo

Royalty Pharma (RPRX) stock

NASDAQ

$68.67+0.21%(+0.14)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

58.53x

P/B

4.02x

P/S

15.05x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 13.3% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 4, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

20 SEC filings
  • Coyne Terrance P.EVP & CFO · Nov 6, 2026Conversion250,000 shares · $0
    Avg. price $0
    Show 2 price lots
    • 100,000 shares × $0$0
    • 150,000 shares × $0$0
  • Urist MarshallEVP, Research & Investments · Nov 6, 2026Conversion150,000 shares · $0
    Avg. price $0150,000 shares held after
  • Urist MarshallEVP, Research & Investments · Nov 4, 2026Grant or award5,341 shares · $0
    Avg. price $05,341 shares held after
  • Hite ChristopherEVP & Chairman, Partnering · Nov 4, 2026Grant or award7,122 shares · $0
    Avg. price $0277,523 shares held after
  • Legorreta Pablo G.CEO, Chairman of the Board · Nov 4, 2026Grant or award42,209 shares · $0
    Avg. price $01,350,029 shares held after
  • Coyne Terrance P.EVP & CFO · Nov 4, 2026Grant or award7,122 shares · $0
    Avg. price $07,122 shares held after
  • Urist MarshallEVP, Research & Investments · Oct 5, 2026Open-market sale4,126 shares · $236K
    Avg. price $57.10 shares held after
  • Bassler Bonnie LDirector · Sep 30, 2026Grant or award642 shares · $37K
    Avg. price $58.405579,823 shares held after
  • Urist MarshallEVP, Research & Investments · Sep 28, 2026Open-market sale4,126 shares · $239K
    Avg. price $57.884,126 shares held after
  • Hite ChristopherEVP & Chairman, Partnering · Sep 22, 2026Open-market sale100,000 shares · $5.9M
    Avg. price $58.531
    Show 2 price lots
    • 96,073 shares × $58.5148$5.6M
    • 3,927 shares × $58.9261$231K
  • Hite ChristopherEVP & Chairman, Partnering · Aug 19, 2026Gift16,800 shares · $0
    Avg. price $023,200 shares held after
  • Hite ChristopherEVP & Chairman, Partnering · Aug 18, 2026Open-market sale100,000 shares · $6.0M
    Avg. price $59.9725370,401 shares held after
  • Coyne Terrance P.EVP & CFO · Aug 13, 2026Open-market sale11,002 shares · $646K
    Avg. price $58.6758
    Show 2 price lots
    • 9,230 shares × $58.5864$541K
    • 1,772 shares × $59.1415$105K
  • Urist MarshallEVP, Research & Investments · Aug 5, 2026Grant or award8,252 shares · $0
    Avg. price $08,252 shares held after
  • Legorreta Pablo G.CEO, Chairman of the Board · Aug 5, 2026Grant or award65,216 shares · $0
    Avg. price $01,307,820 shares held after
  • Hite ChristopherEVP & Chairman, Partnering · Aug 5, 2026Grant or award11,002 shares · $0
    Avg. price $0470,401 shares held after
  • Coyne Terrance P.EVP & CFO · Aug 5, 2026Grant or award11,002 shares · $0
    Avg. price $011,002 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Royalty Pharma (RPRX) stock information

NASDAQ

Royalty Pharma (RPRX) is listed on NASDAQ. Its market capitalization is about $39.4B. On trailing-twelve-month earnings the P/E ratio is 58.53, and the P/B ratio is 4.02. Return on equity is 6.9%. These figures are computed in-house from official filings and are reference information only.

Royalty Pharma — frequently asked questions

What is the P/E ratio of Royalty Pharma (RPRX)?
On a trailing-twelve-month basis, RPRX trades at a P/E ratio of 58.53. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Royalty Pharma?
RPRX has a market capitalization of about $39.4B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.